ArticleTranslational vision science & technology2021
Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments.
Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01610557 (A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
Who cites it
12 citing papers in PubMed.
- Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.The New England journal of medicine · 2022Trial
- Optical Coherence Tomography Biomarkers Differentiate Epiretinal Membranes Secondary to Retinal Detachment from Idiopathic Epiretinal Membranes.Journal of vitreoretinal diseases · 2026Article
- SD-OCT-based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti-VEGF therapy.Acta ophthalmologica · 2026Article
- Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Real-world short-term outcomes after switching to fixed-interval anti-VEGF therapy for neovascular AMD during the COVID-19 pandemic.International journal of retina and vitreous · 2025Article
- Detection of Center-Involved Diabetic Macular Edema With Visual Impairment Using Multimodal Artificial Intelligence Algorithms.Ophthalmology. Retina · 2025Article
- Incidence, Characteristics, and Outcomes of Macular Neovascularization in Extensive Macular Atrophy with Pseudodrusen-like Appearance.Retina (Philadelphia, Pa.) · 2025Article
- Standardized conversion model for retinal thickness measurements between spectral-domain and swept-source optical coherence tomography based on machine learning.Frontiers in cell and developmental biology · 2025Article
- Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.Investigative ophthalmology & visual science · 2024Article
- Investigation of the Reproducibility of Portable Optical Coherence Tomography in Diabetic Macular Edema.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment.Ophthalmology · 2023Article
- Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Purpose: Develop equations to convert Cirrus central subfield thickness (CST) to Spectralis CST equivalents and vice versa in eyes with diabetic macular edema (DME). Methods: The DRCR Retina Network Protocol O data were split randomly to train (70% sample) and validate (30% sample) conversion equations. Data from an independent study (CADME) also validated the equations. Bland-Altman 95% limits of agreement between predicted and observed values evaluated the equations. Results: Protocol O included 374 CST scan pairs from 187 eyes (107 participants). The CADME study included 150 scan pairs of 37 eyes (37 participants). Proposed conversion equations are Spectralis = 40.78 + 0.95 × Cirrus and Cirrus = 1.82 + 0.94 × Spectralis regardless of age, sex, or CST. Predicted values were within 10% of observed values in 101 (90%) of Spectralis and 99 (88%) of Cirrus scans in the validation data; and in 136 (91%) of the Spectralis and 148 (99%) of the Cirrus scans in the CADME data. Adjusting for within-eye correlations, 95% of conversions are estimated to be within 17% (95% confidence interval, 14%-21%) of CST on Spectralis and within 22% (95% confidence interval, 18%-28%) of CST on Cirrus. Conclusions: Conversion equations developed in this study allow the harmonization of CST measurements for eyes with DME using a mix of current Cirrus and Spectralis device images. Translational Relevance: The CSTs measured on Cirrus and Spectralis devices are not directly comparable owing to outer boundary segmentation differences. Converting CST values across spectral domain optical coherence tomography instruments should benefit both clinical research and standard care efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.